Peng Qi1,2,3, Yu Yang1,2,3, Qian-Ming Bai1,2,3, Tian Xue1,2,3, Min Ren1,2,3, Qian-Lan Yao1,2,3, Wen-Tao Yang1,2,3, Xiao-Yan Zhou4,5,6. 1. Department of Pathology, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Shanghai, 200032, China. 2. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 3. Institute of Pathology, Fudan University, Shanghai, 200032, China. 4. Department of Pathology, Fudan University Shanghai Cancer Center, No. 270 Dong An Road, Shanghai, 200032, China. 13524324387@163.com. 5. Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, 200032, China. 13524324387@163.com. 6. Institute of Pathology, Fudan University, Shanghai, 200032, China. 13524324387@163.com.
Abstract
BACKGROUND: Adjuvant therapy decisions may be partly based on the results of a multigene quantitative reverse transcription-polymerase chain reaction (RT-PCR)-based assay: the 21-gene recurrence score (RS) test of resection specimens. When necessary, core needle biopsy (CNB) may be considered as a surrogate. Here, we evaluated the concordance in gene expression according to results from RT-PCR-based RS testing between paired CNBs and resection specimens. METHODS: CNBs and resection specimens from 50 breast cancer (BC) patients were tested to calculate RSs. First, we examined the concordance of the ER, PR and HER-2 status of tissue samples indicated by immunohistochemical (IHC) and RT-PCR analyses. Then, we compared the IHC findings of ER, PR, HER-2 and Ki-67 staining across paired samples. Ultimately, the RS and single-gene results for ER, PR, HER-2 and Ki-67 were explored between paired samples. RESULTS: The concordance between IHC and RT-PCR was 100%, 80.0% and 100% for ER, PR and HER-2, respectively, in both resection specimens and CNBs. The concordance for IHC ER, PR, HER-2 and Ki-67 status was 100%, 94.0%, 52.0% and 82.0%, respectively, between paired samples. RS results from paired samples showed a strong correlation. The overall concordance in RS group classification between samples was 74%, 72% and 78% based on traditional cutoffs, TAILORx cutoffs and ASCO guidelines, respectively. ER, PR, HER-2 and Ki-67 were modestly- to- strongly correlated between paired samples according to the RT-PCR results. CONCLUSION: A modest- to- strong correlation of ER, PR, HER-2 and Ki-67 gene expression and RS between CNBs and resection specimens was observed in the present study. The 21-gene RS test could be reliably performed on CNBs. ER, PR and HER-2 status showed remarkable concordance between the IHC and RT-PCR analyses. The concordance between paired samples was high for the IHC ER, PR and Ki-67 results and low for HER-2.
BACKGROUND: Adjuvant therapy decisions may be partly based on the results of a multigene quantitative reverse transcription-polymerase chain reaction (RT-PCR)-based assay: the 21-gene recurrence score (RS) test of resection specimens. When necessary, core needle biopsy (CNB) may be considered as a surrogate. Here, we evaluated the concordance in gene expression according to results from RT-PCR-based RS testing between paired CNBs and resection specimens. METHODS: CNBs and resection specimens from 50 breast cancer (BC) patients were tested to calculate RSs. First, we examined the concordance of the ER, PR and HER-2 status of tissue samples indicated by immunohistochemical (IHC) and RT-PCR analyses. Then, we compared the IHC findings of ER, PR, HER-2 and Ki-67 staining across paired samples. Ultimately, the RS and single-gene results for ER, PR, HER-2 and Ki-67 were explored between paired samples. RESULTS: The concordance between IHC and RT-PCR was 100%, 80.0% and 100% for ER, PR and HER-2, respectively, in both resection specimens and CNBs. The concordance for IHC ER, PR, HER-2 and Ki-67 status was 100%, 94.0%, 52.0% and 82.0%, respectively, between paired samples. RS results from paired samples showed a strong correlation. The overall concordance in RS group classification between samples was 74%, 72% and 78% based on traditional cutoffs, TAILORx cutoffs and ASCO guidelines, respectively. ER, PR, HER-2 and Ki-67 were modestly- to- strongly correlated between paired samples according to the RT-PCR results. CONCLUSION: A modest- to- strong correlation of ER, PR, HER-2 and Ki-67 gene expression and RS between CNBs and resection specimens was observed in the present study. The 21-gene RS test could be reliably performed on CNBs. ER, PR and HER-2 status showed remarkable concordance between the IHC and RT-PCR analyses. The concordance between paired samples was high for the IHC ER, PR and Ki-67 results and low for HER-2.
Authors: Jan P A Baak; Einar Gudlaugsson; Ivar Skaland; Lydia Hui Ru Guo; Jan Klos; Tone Hoel Lende; Håvard Søiland; Emiel A M Janssen; Axel Zur Hausen Journal: Breast Cancer Res Treat Date: 2008-07-30 Impact factor: 4.872
Authors: Graham A Colditz; Bernard A Rosner; Wendy Y Chen; Michelle D Holmes; Susan E Hankinson Journal: J Natl Cancer Inst Date: 2004-02-04 Impact factor: 13.506
Authors: B Fisher; M Bauer; D L Wickerham; C K Redmond; E R Fisher; A B Cruz; R Foster; B Gardner; H Lerner; R Margolese Journal: Cancer Date: 1983-11-01 Impact factor: 6.860
Authors: Tal Sella; Olga Kantor; Anna Weiss; Ann H Partridge; Otto Metzger; Tari A King Journal: Breast Cancer Res Treat Date: 2022-06-25 Impact factor: 4.624
Authors: Javier I J Orozco; Shu-Ching Chang; Diego M Marzese; Janie G Grumley; Chikako Matsuba; Miquel Ensenyat-Mendez; Gary L Grunkemeier Journal: Ann Surg Oncol Date: 2021-07-09 Impact factor: 5.344
Authors: Soon Bo Choi; Jung Min Park; Jee Hyun Ahn; Jieon Go; Jeeye Kim; Hyung Seok Park; Seung Il Kim; Byeong-Woo Park; Seho Park Journal: Breast Cancer Res Treat Date: 2022-01-13 Impact factor: 4.872
Authors: Jennifer A Crozier; Julie Barone; Pat Whitworth; Abraham Cheong; Robert Maganini; Jose Perez Tamayo; Patricia Dauer; Shiyu Wang; William Audeh; Annuska M Glas Journal: J Surg Oncol Date: 2021-12-29 Impact factor: 2.885